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Abstract: Hypertension is a common and important modifiable risk factor for cardiovascular 
and kidney diseases. The prevalence of hypertension, particularly isolated systolic hypertension, 
increases with advancing age, and this is partly due to the age-related changes in the arterial tree, 
leading to an increase in arterial stiffness. Therapeutic lifestyle changes, such as reduced dietary 
sodium intake, weight loss, regular aerobic activity, and moderation of alcohol consumption, 
have been shown to benefit elderly patients with hypertension. Lowering blood pressure (BP) 
using pharmacological agents reduces the risk for cardiovascular morbidity and mortality, with 
no difference in risk reduction in elderly patients compared to younger hypertensives. Guidelines 
recommend a BP goal of ,140/90 in hypertensive patients regardless of age and ,130/80 in 
patients with concomitant diabetes or kidney disease, and lowering the BP further has not been 
shown to confer any additional benefit. Moreover, the choice of antihypertensive does not seem 
to be as important as the degree of BP lowering. Special considerations in the treatment of 
elderly hypertensive patients include cognitive impairment, dementia, orthostatic   hypotension, 
and polypharmacy.
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Hypertension affects 26.4% of the global population, affecting about 972 million 
individuals worldwide, and patients with elevated blood pressure (BP) are projected 
to comprise 29.2% of the world population in 2025.1 The prevalence of hypertension 
increases with advancing age, such that as much as half of individuals aged between 
60 and 69 years are hypertensive, and this increases to 60%–70% in people above 
the age of 70.1 Further, the lifetime risk for developing hypertension in normotensive 
individuals aged between 55 and 65 years is .90%.2
Hypertension is an important modifiable risk factor for cardiovascular and 
  kidney diseases. Elevations in BP beyond 115/75 mmHg increase the risk for death 
from ischemic heart disease (IHD) and stroke in a log-linear fashion, such that 
the risk of dying from IHD or stroke is doubled for every 20/10 mmHg increase 
in BP.3 After the age of 50, systolic BP (SBP) is more important than diastolic BP 
(DBP) in predicting adverse cardiovascular outcomes. This is attributed to the age-
related increase in SBP, whereas DBP tends to decline after 60 years of age, such 
that majority of elderly individuals have isolated systolic hypertension (ISH) and 
increased pulse pressure (PP).4 The risk for all-cause and cardiovascular death is 
positively correlated to the increase in SBP and PP in elderly patients and inversely 
correlated to DBP.5,6Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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This phenomenon of increased SBP and PP in elderly 
hypertensives is partly explained by increased arterial 
stiffness with advancing age. Structural changes in the arterial 
media, which include declining vascular smooth muscle 
cell number coupled with increased collagen content in the 
vessel wall, calcium deposition, and disruption of elastic 
fibers, result in a markedly stiffer vessel with decreased 
capacitance and loss of recoil.7 The limited expansion of the 
stiff arterial tree (which is most marked at the level of the 
large elastic arteries) leads to a rise in peak BP, whereas 
the limited recoil results in a decline in DBP. These changes 
also result in an increased pulse wave velocity (PWV), where 
pulse waves generated by cardiac contractions are propagated 
faster along the stiff artery. Increased PWV has been shown 
to independently predict cardiovascular mortality and mor-
bidity in elderly patients with hypertension.8 As a corollary, 
increased PWV in middle age (mean 53 ± 17 years old) was 
an independent predictor of longitudinal increase in SBP 
after a mean follow-up of 4.3 years.9
Diagnosis
National guidelines define hypertension and recommend the 
initiation of antihypertensive treatment when the BP exceeds 
140/90 mmHg. In those with diabetes, kidney disease, or 
cardiovascular disease, antihypertensive treatment is recom-
mended if BP exceeds 130/85 mmHg.10–14 Office BP is the 
usual method for BP measurement, and this is ideally per-
formed in a seated patient with the arm propped at the level 
of the heart. The average of two BP readings from the same 
arm is preferred, which is taken after at least 5 min of rest.
After the diagnosis of hypertension is confirmed, the 
evaluation is now directed at assessing lifestyle, looking for 
cardiovascular risk factors, identifying secondary causes 
of hypertension, as well as searching for evidence of target 
organ damage.
Secondary causes
In more than 90% of hypertensive patients, there is no 
identifiable cause for the elevated BP (primary or essential 
hypertension). In the remainder, the elevated BP is attributable 
partly or wholly to a specific cause, which may be potentially 
reversible. Common secondary causes of hypertension in the 
elderly include chronic kidney disease (CKD) and renal artery 
stenosis. Other causes include obstructive sleep apnea, primary 
aldosteronism, Cushing’s disease, pheochromocytoma, hyper-
parathyroidism, aortic coarctation, and intracranial tumors.
CKD can be a cause or a result of hypertension. A decline 
in glomerular filtration rate (GFR) with aging occurs in most 
individuals (but is not inevitable), and this is pronounced in 
those with hypertension and atherosclerosis and in smokers. 
As such, the incidence of CKD increases with advancing age, 
where the odds ratio for the development of CKD is 1.58 and 
5.53 in those aged 40–59 years and those aged 60 years and 
older, respectively.15 In elderly patients with ISH, SBP is a 
strong and independent predictor of the decline in renal func-
tion.16 At present, estimation of the GFR using the Modified 
Diet in Renal Disease formula or the Cockcroft–Gault equa-
tion provides a better gauge of kidney function than serum 
creatinine alone and is preferably paired with a urinalysis to 
check for albuminuria.17 It is important to screen for CKD, 
if present, as this has implications in terms of choice of 
antihypertensive agents and BP goals.
In the elderly, stenosis of the renal artery is often due to 
atherosclerosis. About 7% of individuals aged over 65 years 
have some degree of renal artery narrowing, and 60% of 
patients have hypertension or other evidence of atherosclerotic 
disease (coronary artery disease or peripheral arterial 
disease).18 Renal artery stenosis should be suspected in an 
elderly patient who presents with new onset or accelerated 
hypertension (with worsening BP control), in patients with 
resistant hypertension (who need three or more medica-
tions to bring the BP to goal), in patients with asymmetric 
kidneys on imaging (a difference of greater than 1.5 cm), 
and in those who present with flash pulmonary edema or 
acute renal failure after initiating renin–angiotensin system 
blocker therapy (angiotensin-converting enzyme [ACE] 
inhibitors, angiotensin receptor blockers [ARB], or direct 
renin inhibitors).19 Imaging techniques used to evaluate the 
patency of the renal artery include renal Doppler ultrasound, 
computed tomography angiography, and magnetic resonance 
angiography and are used as screening tests. The gold standard 
for diagnosis remains renal artery angiography. Treatment 
includes modification of cardiovascular risk factors, antihy-
pertensive therapy, and in eligible patients, revascularization, 
but this has not consistently been shown to normalize BP in 
hypertensive patients.18
Treatment
Lifestyle changes
Important lifestyle modifications to help lower BP in hyper-
tensive patients include dietary sodium reduction, weight 
loss and maintenance of ideal body weight, regular aerobic 
activity, and moderation of alcohol intake (Table 1). The Trial 
of Non-Pharmacologic Interventions in the Elderly (TONE) 
randomized 975 patients aged 60–80 years with hypertension 
(BP , 145/85 mmHg while taking one antihypertensive Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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medication) to sodium reduction, weight loss, a combination 
of both, or usual care for the obese participants and to sodium 
reduction and usual care in the nonobese patients.20 The study 
participants attended group intervention sessions, and 90 days 
after their first session, the patients were weaned from their 
antihypertensive medication, with a goal of discontinuing the 
drug altogether. The primary endpoints were the finding of 
elevated BP (SBP . 190 mmHg or DBP . 110 mmHg at 
one study visit; or mean SBP . 170 mmHg or mean DBP 
. 100 mmHg over two sequential visits; or mean SBP . 
150 mmHg or mean DBP . 90 mmHg over three sequential 
visits) at one or more study visits after drug discontinuation 
or weaning, the need to reinstitute antihypertensive therapy, as 
well as cardiovascular events (myocardial infarction, stroke, 
congestive heart failure, angioplasty, or coronary bypass 
surgery), and death.
The obese participants in TONE who were randomized 
to the weight loss and combination arms were given a 
weight loss goal of −4.5 kg, using a combination of diet and 
increased physical activity. The average weight loss among 
participants in the weight loss arm was 3.5 kg, and 47% 
achieved the goal of −4.5 kg after 9 months. This resulted 
in 39% of subjects in the weight loss arm not experiencing a 
rise in BP or a need to reinstitute BP-lowering medications 
for 30 months after discontinuing antihypertensive drugs. 
In patients who were randomized to the sodium reduc-
tion and combination arms, only 36% achieved the goal 
to reduce sodium intake to ,80 mmol/day (1.8 g/day). In 
spite of this, 72% of those assigned to a low-sodium diet had 
their BP controlled to ,140/90 mmHg, and 38% of these 
remained off antihypertensive medications for 30 months. 
The mean SBP and DBP values prior to the initiation of 
antihypertensive drug withdrawal were significantly lower 
in all intervention groups compared to usual care. TONE 
showed that nonpharmacological interventions to lower BP, 
particularly reduced sodium intake and weight loss (via diet 
and increased physical activity), result in clinically important 
reductions in need for antihypertensive medications in elderly 
hypertensive patients.
In addition to reduction of sodium, a diet rich in fruits, 
vegetables, and low-fat dairy products, with limited cho-
lesterol and saturated fat, is recommended for hypertensive 
patients (the Dietary Approaches to Stop Hypertension or 
the DASH diet), except for those with CKD, in whom the 
increased potassium and protein may be harmful.21 Dietary 
modification is an important nonpharmacological interven-
tion to reduce BP in elderly patients with hypertension.
In elderly hypertensive patients, regular aerobic exercise, 
consisting of a minimum of 30 min of interval training on a 
treadmill done three times a week, has been shown to be well 
tolerated and beneficial.22 Adherence to the 12-week exercise 
program in this study lowered SBP by 8.5 mmHg, DBP by 
5.1 mmHg, and PP by 3.2 mmHg from baseline on 24-h 
ambulatory BP monitoring in elderly hypertensive patients 
on a stable antihypertensive drug regimen. This effect was 
not seen in the control group, who were sedentary, in whom 
the BP values were similar at baseline and after 12 weeks 
of follow-up. Further, there was marked improvement of 
physical performance in the exercise group compared to 
the sedentary group, as measured by a rightward shift in 
the lactate and heart rate curves after 12 weeks. One patient 
dropped out from the study due to knee pain, and another 
developed acute cholecystitis after 4 weeks; otherwise, no 
severe adverse events were noted during the course of the 
study. In elderly hypertensive patients without contraindi-
cations, regular physical activity is beneficial and safe and 
should be encouraged.
Pharmacological treatment
Benefits of pharmacological treatment  
of hypertension in the elderly
In elderly hypertensive patients, lowering the BP reduces the 
risk for cardiovascular morbidity and mortality. The benefits 
achieved with BP reduction in the elderly are similar to that in 
younger hypertensive patients. The Blood Pressure Lowering 
Treatment Trialists’ Collaboration pooled data from 31 trials, 
involving 190,606 individuals, that compared active antihy-
pertensive treatment to placebo or a less intensive regimen, 
as well as trials that compared different antihypertensive 
regimens.23 It showed that there was no difference in the 
incidence of cardiovascular outcomes (fatal and nonfatal 
stroke, coronary heart disease, and heart failure) in patients 
aged 65 years and older compared to hypertensive individuals 
Table 1 Degree of BP reduction achieved with lifestyle modifications in 
elderly patients with hypertension
Intervention Definition Degree of SBP/DBP 
(mmHg) reduction
Dietary sodium  
restriction
Limit sodium intake 
to ,80 mmol/day
3.4–7.2/1.9–3.2
Increased physical  
activity
Aerobic activity lasting  
30 min, done thrice 
weekly
8.5/5.1
weight reduction weight loss of 4.5 kg 4/1.1
Limiting alcohol  
intake
Limit alcohol intake 
to ,2 drinks/day
1.2/0.7
Notes: Copyright © 2009. Reproduced with permission from elsevier. Acelajado 
MC, Oparil SO. Hypertension in the elderly. Clin Geriatr Med. 2009;25: 391–492.41Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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aged under than 65 years. Further, there was no difference in 
the risk reduction achieved between the two age groups per 
unit reduction in BP. There was also no interaction between 
age and the effects of treatment on the primary outcome for 
any antihypertensive regimen compared to control.
Individual trials quantify the magnitude of risk reduc-
tion achieved with BP lowering. The Systolic Hyperten-
sion in the Elderly Program (SHEP) evaluated the ability 
of chlorthalidone with or without atenolol versus placebo 
in reducing the risk of fatal and nonfatal stroke in elderly 
patients ($60 years old) with ISH.24 Compared to placebo, 
active treatment reduced the risk of stroke by 36% after an 
average of 4.5 years of follow-up (P = 0.0003). The Systolic 
Hypertension in Europe trial (SYST-EUR) was done on 
4695 patients who were $60 years old with ISH (SBP on 
study entry .160 mmHg).25 The study participants were 
randomized to receive either nitrendipine 10–40 mg/day with 
the possible addition of enalapril 5–20 mg/day and hydrochlo-
rothiazide 12.5–25 mg/day or matching placebos. SYST-EUR 
showed that active treatment reduced the rate of primary 
endpoints (fatal and nonfatal stroke) by 42% (P = 0.003) 
and all fatal and nonfatal cardiovascular endpoints (stroke, 
retinopathy, myocardial infarction, congestive heart failure, 
and renal insufficiency) by 31% (P , 0.001) compared to 
placebo after a mean follow-up of 2 years. A similar study, the 
Systolic Hypertension in China trial (SYST-CHINA), which 
randomized 2394 hypertensive patients aged 60 or older, dem-
onstrated that active treatment (nitrendipine 10–40 mg/day, 
with the addition of captopril 12.5–50 mg/day or hydrochlo-
rothiazide 12.5–25 mg/day or both, is administered to achieve 
an SBP goal of ,150 mmHg) reduced the incidence of total 
strokes by 38% (P = 0.01), stroke deaths by 58% (P = 0.02), 
cardiovascular mortality by 39% (P = 0.03), and all fatal and 
nonfatal cardiovascular endpoints (similar to the SYST-EUR 
trial) by 37% (P = 0.004) compared to placebo.26
A meta-analysis of eight trials on elderly hypertensive 
patients has shown that antihypertensive treatment reduced 
total mortality by 13% (P = 0.02), cardiovascular deaths by 
18%, stroke by 30%, and coronary events by 23% compared 
to control (placebo or a less intensive antihypertensive 
regimen).6 The absolute benefit was found to be higher in 
men, in patients who were .70 years old, and in those with 
previous cardiovascular disease or higher PP. These data 
provide strong support that BP lowering in the elderly sig-
nificantly reduces cardiovascular risk.
Early treatment of hypertension in elderly patients as 
opposed to delayed treatment also produces greater cardio-
vascular risk lowering. In the open-label follow-up of 3517 
patients from the SYST-EUR Study (where median follow-up 
was 6.1 years), those who had received active treatment during 
the double-blind phase of the trial had 28% less incidence of 
stroke and 15% less cardiovascular complications compared 
to those patients who were randomized to receive placebo 
during that period (P = 0.01 and P = 0.03, respectively).27 
Given the high incidence of ISH in the elderly population, 
early recognition and initiation of therapy are important.
Lastly, the benefit of hypertension treatment has been 
shown to persist long after the termination of studies. In 
the 14-year follow-up of SHEP participants, those who had 
received active treatment with chlorthalidone with or without 
atenolol during the trial had fewer deaths from cardiovas-
cular causes (P = 0.016), without a significant difference 
in all-cause mortality or stroke deaths compared to those 
randomized to placebo.28 Further, those who had sustained 
a stroke during the trial had a worse prognosis compared 
to those who were stroke free, and the predictors of death 
included SBP, diabetes, and smoking, which are modifiable. 
This highlights the fact that in elderly hypertensive patients 
who had a stroke, control of modifiable cardiovascular risk 
factors may help decrease the long-term risk of death.
Goal of antihypertensive therapy
The guidelines in the management of hypertension recom-
mend a BP goal of ,140/90 mmHg in hypertensive patients 
and ,130/80 in patients with diabetes and kidney diseases, 
irrespective of age.10–14 While at best prudent, it is not backed 
by solid evidence showing that treating hypertension to these 
BP goals provides additional cardiovascular risk reduction. 
Major placebo-controlled trials involving elderly hypertensive 
patients enrolled individuals with a baseline SBP . 160 mmHg, 
and the treatment goal was ,150 mmHg in most studies. In a 
prospective study done in Italy, 1111 nondiabetic hypertensive 
patients (mean age 67) were randomized to receive open-label 
antihypertensive treatment to lower SBP to ,140 mmHg in 
one group and ,130 mmHg in another.29 The primary end-
point was the incidence of left ventricular hypertrophy after 
2 years of follow-up. The study showed that patients who 
were randomized to SBP lowering to ,130 mmHg had less 
incidence of left ventricular hypertrophy compared to those 
randomized to the SBP goal of ,140 mmHg (11.4% and 17%, 
respectively, P = 0.013). The difference in SBP achieved after 
the 2-year follow-up between the two groups, however, was 
only 3.8 mmHg, so the effect of choice of antihypertensive 
medication may have influenced the results.
In the Action to Control Cardiovascular Risk in Diabetes–
Blood Pressure trial (ACCORD BP), 4733 middle-aged and Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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elderly participants (mean age 62 years) with type 2 diabetes 
mellitus and established cardiovascular disease, evidence of 
target organ damage, or at least two cardiovascular risk factors 
were randomly assigned in a 2 × 2 factorial design to intensive 
(SBP , 120 mmHg) versus standard (SBP , 140 mmHg) 
BP control.30 Antihypertensive medications were given open-
label, and the study did not specify the drug class that would be 
used for lowering BP in both groups. After a mean follow-up 
of 4.7 years, the BP decreased from a mean of 139/76 mmHg 
in both groups to 119/64 mmHg in the intensive BP-lowering 
group and 133/70 mmHg in the standard control group, which 
resulted in a 14/6 mmHg difference between the two groups 
(Figure 1). As expected, those in the intensive BP-lowering 
group were on greater numbers of antihypertensive agents. 
There was no significant difference between the two groups 
in the incidence of major cardiovascular events, which include 
the composite of nonfatal myocardial infarction, nonfatal 
stroke, and cardiovascular death. Moreover, there was a higher 
incidence of adverse events in the intensive treatment group 
that are attributable to antihypertensive therapy, which include 
hypotension, syncope, bradycardia, and arrhythmia, as well 
as hypokalemia and elevations in serum creatinine. On the 
other hand, there was a significant reduction in the incidence 
of total stroke and nonfatal stroke (which are two of several 
prespecified secondary outcomes) in the intensive BP con-
trol compared to standard BP control. The ACCORD Study, 
however, is limited by the low occurrence of cardiovascular 
events during the study duration in the standard control group, 
which may have minimized a probable difference in outcomes, 
if any, between the two groups. Nevertheless, the ACCORD 
results, while showing that SBP lowering to ,120 mmHg 
reduces the risk for stroke, did not support further lower-
ing of SBP beyond 140 mmHg in improving cardiovascular 
outcomes in middle-aged and elderly hypertensive patients 
with diabetes and may in fact lead to a higher incidence of 
adverse effects related to treatment. Whether this is true for 
nondiabetic elderly patients and older patients with kidney 
disease is still controversial.
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Figure 1 Comparison of intensive versus standard BP lowering on the composite of nonfatal stroke, nonfatal myocardial infarction, and death from cardiovascular disease 
(primary outcome). Copyright © 2010. Adapted with permission from Massachusetts Medical Society. All rights reserved. Cushman wC, evans Gw, Byington RP, et al., for 
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Choice of antihypertensive agents
The presence of comorbidities, history of adverse reactions 
to medications, cost, ease of dosage, and patient preference 
influence the choice of antihypertensive agents in elderly 
patients. A large meta-analysis has shown that the choice 
of antihypertensive agent does not influence outcomes, 
ie, the benefit derived from BP reduction is similar in 
magnitude and independent of the antihypertensive agent 
used to create such effect, regardless of the patient’s age.23 
Data comparing diuretics or beta blockers (BB) versus ACE 
inhibitors or calcium channel blockers (CCB), as well as ACE 
inhibitors versus CCB, show that there was no difference in 
the proportional reduction of cardiovascular risk between the 
different antihypertensive regimens in patients .65 years of 
age (Figure 2). Diuretics, ACE inhibitors, ARB, BB, CCB, 
and aldosterone antagonists, either singly or in combination, 
are all acceptable options as initial antihypertensive agents 
in elderly patients. Guidelines in managing hypertensive 
patients specify particular agents to use in certain disease 
conditions, such as coronary artery disease, renal disease, 
and diabetes, where the preferred agent has been found, in 
clinical trials, to have favorable effects in specific clinical 
settings.
Most hypertensive patients would need two or more 
antihypertensive agents to bring the BP to goal. Combination 
therapy using agents with complementary mechanisms of 
action is favorable because it allows the use of antihyperten-
sive medications at lower doses than if the medication was 
used singly, thereby also minimizing the incidence of adverse 
effects. Further, the use of combination therapy at the outset, 
particularly in high-risk patients, reduces cardiovascular risk 
by giving early BP control.11 Fixed-dose combination pills 
are preferred by most physicians and are recommended by 
certain guidelines as they may lower overall cost and improve 
adherence to treatment.31
Acceptable antihypertensive drug combinations include a 
renin–angiotensin system blocker and a diuretic or CCB, as 
well as BB and a diuretic. Several trials have demonstrated the 
benefit of these combinations in reducing cardiovascular risk 
in elderly patients with hypertension. For example, in SHEP, 
chlorthalidone with atenolol reduced the risk for fatal and 
nonfatal stroke compared to placebo.24 SYST-EUR (where as 
much as 80% of the study participants were on combination 
antihypertensive therapy during the first year of the trial) and 
SYST-CHINA showed that CCB-based therapy combined 
with an ACE inhibitor and a thiazide diuretic reduced the 
incidence of fatal and nonfatal cardiovascular events, particu-
larly fatal and nonfatal stroke, and the composite of fatal and 
nonfatal cardiovascular endpoints.25,26 Other large outcome 
trials, which did not exclusively involve elderly patients, 
have also shown that combination antihypertensive therapy 
is beneficial. The Anglo-Scandinavian Cardiac Outcomes 
Trial–Blood Pressure Lowering Arm, conducted in 19,257 
high-risk hypertensive patients (mean age 63 ) and comparing 
amlodipine with or without perindopril versus atenolol with 
or without bendroflumethiazide, found that the treatment 
based on amlodipine was superior in preventing a compos-
ite of cardiovascular mortality, myocardial infarction, and 
stroke with a similar degree of BP reduction.32 The Avoiding 
Cardiovascular Events thru Combination Therapy in Patients 
Living with Systolic Hypertension (ACCOMPLISH) trial, 
which had a predominantly elderly patient population (mean 
age 68), demonstrated that an ACE inhibitor–CCB combina-
tion (benazepril and amlodipine) was effective in preventing 
a composite of fatal and nonfatal cardiovascular endpoints 
and was superior (19.6% less events) to a combination of an 
ACE inhibitor and a diuretic (benazepril and hydrochloro-
thiazide) in spite of a similar degree of BP reduction in both 
groups.33 The last two studies imply that cardiovascular risk 
lowering is not entirely dependent on BP lowering in some 
antihypertensive treatment trials.
Figure 2 Comparison of different BP-lowering regimens in reducing cardiovascular 
risk  in  hypertensive  patients  .65  years  old.  A)  Angiotensin-converting  enzyme 
inhibitor versus diuretic or beta blocker. B) Calcium antagonist versus diuretic or 
beta blocker. C) Angiotensin-converting enzyme inhibitor versus calcium antagonist. 
Copyright © 2008. Adapted with permission from BMJ Publishing Group Ltd. Turnbull 
F, for the Blood Pressure Lowering Treatment Trialists’ Collaboration. effects of 
different regimens to lower blood pressure on major cardiovascular events in older 
and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–1123.23
Favors first
listed
1.0 0.52 .0
Favors second
listed 
A
B
C
Risk ratio
Age > 65
1.01 (0.95 – 1.06)
1.02 (0.97 – 1.06)
0.98 (0.92 – 1.05)Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
151
Optimal management of hypertension
Treating the very elderly
In the past, treatment of BP in the very elderly was con-
troversial. This subgroup of patients is usually excluded 
from clinical trials, and the data available to demonstrate 
treatment benefits were limited and inconclusive. Further, 
the benefits of antihypertensive therapy could be potentially 
offset by complications of treatment, which are seen as 
occurring more commonly in the elderly, such as dementia, 
orthostatic hypotension, heart failure, and electrolyte abnor-
malities. This clinical uncertainty with regards to the relative 
benefits and risks associated with antihypertensive therapy 
in patients .80 years old was addressed by the Hyperten-
sion in the Very Elderly Trial (HYVET). HYVET enrolled 
3845 hypertensive patients who were .80 years old with a 
baseline SBP .160 mmHg and randomized them to receive 
indapamide or placebo.34 Perindopril or placebo was added 
on later if the BP was still above goal (,150/80 mmHg). The 
results show that active treatment was associated with a 30% 
reduction in fatal or nonfatal stroke (P = 0.06), a 39% reduc-
tion in stroke deaths (P = 0.06), a 21% decrease in all-cause 
mortality (P = 0.02), and a 23% decline in cardiovascular 
death after a median follow-up of 1.8 years. Further, there 
was a 64% reduction of heart failure (P , 0.001). This was 
achieved without an excess of adverse events in the active 
treatment arm compared to placebo. The incidence of potas-
sium abnormalities or increase in serum creatinine, uric acid, 
or glucose was similar in the active and placebo treatment 
arms. Orthostatic hypotension occurred in 12% of study 
participants in the pilot trial, but the authors counter that 
this higher than expected number could be due to selection 
bias as those with SBP .140 mmHg were excluded from the 
analysis.35 This trial gave conclusive evidence that even in 
the very elderly (.80 years old), treatment of hypertension 
reduces cardiovascular risk significantly. A caveat, however, 
is that HYVET excluded nursing home residents, patients 
with dementia, and those with kidney disease or heart fail-
ure, which comprise a significant subset in this age group; 
hence, these results may not be generalized to all elderly 
patients .80 years of age.
Other considerations in the treatment  
of elderly hypertensive patients
The treatment of elderly hypertensive patients is compli-
cated by many factors. Orthostatic hypotension, defined as a 
supine-to-standing BP difference of −20/−10 mmHg, occurs 
more commonly in the elderly, owing to a blunted barore-
flex response that occurs with standing.36 Initiating antihy-
pertensive medications at low doses and making gradual 
adjustments, and obtaining a standing BP when increasing 
medication doses in symptomatic patients are part of a good 
practice. In addition, elderly patients frequently take multiple 
medications for other comorbid conditions, so the possibil-
ity of drug interactions is high. This is particularly true for 
nonsteroidal anti-inflammatory drugs, which may interfere 
with the actions of antihypertensive medications, and may 
lead to poor BP control.37 Polypharmacy may also lead to 
poor compliance in elderly patients, so simplification of the 
drug regimen is encouraged.
Cognitive impairment is common in the elderly popula-
tion. Hypertension has been implicated in the pathogen-
esis of cognitive impairment and dementia in the elderly. 
Elevated BP during middle age predicts the development of 
dementia with aging.38 Further, a high SBP (.180 mmHg) 
and a low DBP (,70 mmHg) increase the risk of dementia 
in older adults.39 Antihypertensive treatment lowers this 
risk as shown in SYST-EUR, where active treatment is 
associated with a 65% lower risk of dementia compared to 
placebo.40 In treating hypertensive patients with cognitive 
impairment, simplifying the treatment regimen, regular 
follow-ups, and involving caregivers are all part of optimal 
BP management.
Summary
Hypertension is a common and very important modifiable 
risk factor for cardiovascular morbidity and mortality. The 
prevalence of hypertension increases with advancing age, 
and this is accounted for partly by age-related changes in the 
arterial tree. Initiating antihypertensive treatment is recom-
mended when BP exceeds 140/90 mmHg (130/85 mmHg 
in those with diabetes, kidney disease, and cardiovascular 
disease). Therapeutic lifestyle changes should be encour-
aged in elderly hypertensive patients and include dietary 
sodium restriction, increased physical activity, weight loss 
and maintenance of ideal body weight, and moderation 
of alcohol consumption. In the elderly, pharmacological 
treatment of hypertension provides significant reductions in 
cardiovascular risk. The degree of BP reduction achieved 
appears to be more important than the choice of antihyper-
tensive agent, and this is true for younger and older patients. 
Combination antihypertensive therapy is usually indicated 
in elderly hypertensive patients, and acceptable regimens 
include a renin–angiotensin system blocker and a diuretic 
or a CCB. Treatment of hypertension in elderly patients is 
confounded by a greater tendency to develop orthostatic 
hypotension, polypharmacy, and a higher incidence of 
cognitive impairment.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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